VAERS reports by lot

Merck HPV lot 0420AE: VAERS reports

50 VAERS reports list lot 0420AE as a Merck HPV vaccine, received between 2012-06-12 and 2018-07-03. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
50
Reports
36%
Marked serious
0
With a death outcome
24
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)3422%
Neurological2818%
Gastrointestinal1711%
Cardiac / Cardiovascular1610%
Musculoskeletal149%
Dermatological (non-injection-site)149%
Injection-site / Local reaction128%
Allergic / Anaphylactic64%
Psychiatric / Neuropsychiatric53%
Autoimmune / Immune-mediated32%
Thrombotic / Hematological21%
Respiratory11%
Reproductive / Menstrual11%

Where reports came from

U.S. state of the reporter, where given (top 12).

Florida5
California3
Texas3
Ohio3
Michigan3
Connecticut2
Mississippi2
Pennsylvania2
District of Columbia2
North Carolina2
Maryland2
Utah1

Reports by month received

2012-061
2012-092
2012-103
2012-111
2012-123
2013-011
2013-025
2013-037
2013-045
2013-056
2013-061
2013-071
2013-082
2013-091
2013-111
2013-121
2014-042
2014-051
2014-071
2015-011
2015-031
2015-091
2016-031
2018-071

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.